Literature DB >> 35239125

Association between changes in lipid indexes and early progression of kidney dysfunction in participants with normal estimated glomerular filtration rate: a prospective cohort study.

Qi Zhai1, Jingtao Dou2, Jing Wen1, Meiping Wang1, Yingting Zuo1, Xin Su1,3, Yibo Zhang1, Herbert Gaisano4, Yiming Mu5, Yan He6,7.   

Abstract

PURPOSE: To investigate whether non-high-density lipoprotein cholesterol (Non-HDL-C), remnant cholesterol (RC), and the ratios of lipid indexes are more closely associated with early progression of kidney dysfunction than traditional lipid indexes; and to explore the association between changes in serum lipids during follow-up and annual decline rate in estimated glomerular filtration rate (eGFR).
METHODS: In this prospective cohort study, 3909 participants with normal eGFR and age≥40 years at baseline were followed for 3.3 years. Progression of kidney dysfunction was assessed as annual decline rate in eGFR. Spearman correlation analysis, linear correlation models, and multiple logistic regression were used to assess the associations between lipid indexes at baseline/both baseline and follow-up and the annual decline rate in eGFR.
RESULTS: Compared with ΔLDL-C (β = 0.412), other lipid indexes such as ΔLDL-C/HDL-C (β = 0.565), ΔTC/HDL-C (β = 0.448), and ΔNon-HDL-C/HDL-C (β = 0.448) were more closely associated with annual decline rate in eGFR. High TG/HDL-C (OR = 1.699(1.177-2.454)) and TC/HDL-C (OR = 1.567(1.095-2.243)) at baseline, as well as high TC/HDL-C (OR = 1.478 (1.003-2.177)) and TG/HDL-C (OR = 1.53(1.044-2.244)) at both baseline and follow-up were associated with the annual decline rate in eGFR <0.5. High Non-HDL-C (OR = 1.633(1.025-2.602)) and LCI (OR = 1.631(1.010-2.416)) at both baseline and follow-up resulted in a 63% increase in risk of annual decline rate in eGFR >1.
CONCLUSION: High Non-HDL-C, RC and the ratios of lipid indexes were more closely associated with early progression of kidney injury than the increase of traditional lipid indexes. These lipid indexes should be monitored, even in participants with normal traditional serum lipid levels.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Dyslipidemia; Estimated glomerular filtration rate; Lipid changes; Non-high-density lipoprotein cholesterol; Serum lipids; The ratios of lipid indexes

Mesh:

Substances:

Year:  2022        PMID: 35239125     DOI: 10.1007/s12020-022-03012-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  24 in total

1.  Diabetic nephropathy.

Authors:  Mark E Molitch; Ralph A DeFronzo; Marion J Franz; William F Keane; Carl Erik Mogensen; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

2.  Urine volume and change in estimated GFR in a community-based cohort study.

Authors:  William F Clark; Jessica M Sontrop; Jennifer J Macnab; Rita S Suri; Louise Moist; Marina Salvadori; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

Review 3.  Hyperlipidemia in patients with chronic renal disease.

Authors:  B L Kasiske
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

4.  Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.

Authors:  Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

Review 5.  GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

Authors:  Andrew S Levey; Lesley A Inker; Kunihiro Matsushita; Tom Greene; Kerry Willis; Edmund Lewis; Dick de Zeeuw; Alfred K Cheung; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2014-10-16       Impact factor: 8.860

6.  Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.

Authors:  Andrew S Levey; Ron T Gansevoort; Josef Coresh; Lesley A Inker; Hiddo L Heerspink; Morgan E Grams; Tom Greene; Hocine Tighiouart; Kunihiro Matsushita; Shoshana H Ballew; Yingying Sang; Edward Vonesh; Jian Ying; Tom Manley; Dick de Zeeuw; Kai-Uwe Eckardt; Adeera Levin; Vlado Perkovic; Luxia Zhang; Kerry Willis
Journal:  Am J Kidney Dis       Date:  2019-08-28       Impact factor: 8.860

Review 7.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

8.  Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease.

Authors:  Anum Saeed; Elena V Feofanova; Bing Yu; Wensheng Sun; Salim S Virani; Vijay Nambi; Josef Coresh; Cameron S Guild; Eric Boerwinkle; Christie M Ballantyne; Ron C Hoogeveen
Journal:  J Am Coll Cardiol       Date:  2018-07-10       Impact factor: 24.094

9.  Cohort profile: risk evaluation of cancers in Chinese diabetic individuals: a longitudinal (REACTION) study.

Authors:  Yufang Bi; Jieli Lu; Weiqing Wang; Yiming Mu; Jiajun Zhao; Chao Liu; Lulu Chen; Lixin Shi; Qiang Li; Qin Wan; Shengli Wu; Tao Yang; Li Yan; Yan Liu; Guixia Wang; Zuojie Luo; Xulei Tang; Gang Chen; Yanan Huo; Zhengnan Gao; Qing Su; Zhen Ye; Youming Wang; Guijun Qin; Huacong Deng; Xuefeng Yu; Feixia Shen; Li Chen; Liebin Zhao; Jie Zhang; Jichao Sun; Meng Dai; Min Xu; Yu Xu; Yuhong Chen; Shenghan Lai; Zachary T Bloomgarden; Donghui Li; Guang Ning
Journal:  J Diabetes       Date:  2014-01-09       Impact factor: 4.006

10.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Rafael Lozano; Mohsen Naghavi; Kyle Foreman; Stephen Lim; Kenji Shibuya; Victor Aboyans; Jerry Abraham; Timothy Adair; Rakesh Aggarwal; Stephanie Y Ahn; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Suzanne Barker-Collo; David H Bartels; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Kavi Bhalla; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; Fiona Blyth; Ian Bolliger; Soufiane Boufous; Chiara Bucello; Michael Burch; Peter Burney; Jonathan Carapetis; Honglei Chen; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Diego De Leo; Louisa Degenhardt; Allyne Delossantos; Julie Denenberg; Don C Des Jarlais; Samath D Dharmaratne; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Patricia J Erwin; Patricia Espindola; Majid Ezzati; Valery Feigin; Abraham D Flaxman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Sherine E Gabriel; Emmanuela Gakidou; Flavio Gaspari; Richard F Gillum; Diego Gonzalez-Medina; Yara A Halasa; Diana Haring; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Bruno Hoen; Peter J Hotez; Damian Hoy; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Ganesan Karthikeyan; Nicholas Kassebaum; Andre Keren; Jon-Paul Khoo; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Michael Lipnick; Steven E Lipshultz; Summer Lockett Ohno; Jacqueline Mabweijano; Michael F MacIntyre; Leslie Mallinger; Lyn March; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; John McGrath; George A Mensah; Tony R Merriman; Catherine Michaud; Matthew Miller; Ted R Miller; Charles Mock; Ana Olga Mocumbi; Ali A Mokdad; Andrew Moran; Kim Mulholland; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Kiumarss Nasseri; Paul Norman; Martin O'Donnell; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; David Phillips; Kelsey Pierce; C Arden Pope; Esteban Porrini; Farshad Pourmalek; Murugesan Raju; Dharani Ranganathan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Frederick P Rivara; Thomas Roberts; Felipe Rodriguez De León; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Joshua A Salomon; Uchechukwu Sampson; Ella Sanman; David C Schwebel; Maria Segui-Gomez; Donald S Shepard; David Singh; Jessica Singleton; Karen Sliwa; Emma Smith; Andrew Steer; Jennifer A Taylor; Bernadette Thomas; Imad M Tleyjeh; Jeffrey A Towbin; Thomas Truelsen; Eduardo A Undurraga; N Venketasubramanian; Lakshmi Vijayakumar; Theo Vos; Gregory R Wagner; Mengru Wang; Wenzhi Wang; Kerrianne Watt; Martin A Weinstock; Robert Weintraub; James D Wilkinson; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Paul Yip; Azadeh Zabetian; Zhi-Jie Zheng; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.